First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration Expands CNSide contracted payer access to approximately 164 million covered lives HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of…